---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009861"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T15:06:54.298482+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics licenses CRISPR/Cas9 to Vertex for $100M upfront; eligible for $230M milestones

## Summary
- Vertex pays $100M upfront for non-exclusive rights to CRISPR/Cas9 for hypoimmune cell therapies in type 1 diabetes.
- CRISPR eligible for up to $230M in research and development milestones plus low-to-mid single-digit royalties.
- Vertex's existing T1D programs VX-880 and VX-264 are not included; CRISPR retains ViaCyte collaboration.
- Agreement expands existing relationship; Phase 1/2 study of VCTX211 (gene-edited stem cell therapy) is ongoing.

## SEC filing metadata
- accession: 0000950170-23-009861
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023009861/0000950170-23-009861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023009861/crsp-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009861
- JSON: https://secwatch.observer/filing/0000950170-23-009861.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009861.txt

## Key facts
- Material Agreements
  CRISPR Therapeutics AG entered into Non-Exclusive License Agreement with Vertex Pharmaceuticals Incorporated valued at $100.0 million (effective 2023-03-23).
  - Action: entry
  - Agreement: license
  - Counterparty: Vertex Pharmaceuticals Incorporated
  - Value: $100.0 million
  - Effective: 2023-03-23
  source text: On March 23, 2023, CRISPR Therapeutics AG (“CRISPR”) entered into a Non-Exclusive License Agreement (the “Non-Ex License”) with Vertex Pharmaceuticals Incorporated (“Vertex”), pursuant to which CRISPR agreed to license to Vertex, on a non-exclusive basis, certain of its gene editing intellectual property to exploit certain products for the diagnosis, treatment or prevention of diabetes type 1, diabetes type 2 or insulin dependent/requiring diabetes throughout the world.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017023009861/0000950170-23-009861-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.